Descriptors and administrative fields exactly as published in the CMS HCPCS quarterly file.
Billing context: J-codes
Units are reported in multiples of the dosage in the code descriptor.
One HCPCS billing unit of J0290
500 MG
Medicare payment limit per unit (Q4 2026): $0.619
| Setting | Max units / day | Adjudication (MAI) | CMS rationale |
|---|---|---|---|
| Practitioner services (professional claims) | 24 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. | Clinical: Data |
| Facility outpatient hospital services | 24 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. | Clinical: Data |
| DME supplier services | 0Not reportable in this setting | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. |
Medicare Part B drug payment limits per billing unit, by quarter, from the CMS payment limit (ASP) files.
Current Medicare Part B payment limit · Q4 2026
$0.619per 500 MG
Effective Oct 1, 2026 – Dec 31, 2026 · ASP methodology (per CMS file) · based on Q2 2026 ASP data · coinsurance 20.000%
| Quarter | Effective | Payment limit | Per (billing unit) | Coinsurance | Change | CMS notes |
|---|---|---|---|---|---|---|
| Q4 2026 | Oct 1, 2026 – Dec 31, 2026 | $0.619 | 500 MG | 20% | +0.8% | — |
| Q3 2026 | Jul 1, 2026 – Sep 30, 2026 | $0.614 | 500 MG | 20% | −4.4% |
Medicare hospital outpatient (OPPS) · Q4 2026
N Packaged: no separate payment
Washington Apple Health · professional claims
AAC = actual acquisition cost, based on NDC or invoice; BR = by report; NC = not covered; DC = not covered, see a different code; DP = covered under another program (see comments); PA = prior authorization; EPA = expedited prior authorization (see the billing guide); CPA = contractor prior authorization (Qualis). For professional claims; hospital-administered drugs are paid under HCA's outpatient (OPPS/EAPG) rules.
Packages CMS assigns to this code in its NDC–HCPCS crosswalks, with billable units per package. Only official crosswalk rows are shown.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Derived $ / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|---|
| 50090-4552-00 | Ampicillin SodiumA-S Medication Solutions | 1 × 1 | 4 | 4 | $2.48 | ASP | Q1 2021 – Q4 2026 | Excluded listingAmpicillin |
| 72485-0421-10 | Ampicillin SodiumArmas Pharmaceuticals Inc. | 1 × 10 | 2 | 20 | $12.38 | ASP | Q3 2024 – Q4 2026 | ListedAmpicillin |
| 72485-0422-10 | Ampicillin SodiumArmas Pharmaceuticals Inc. | 1 × 10 | 4 | 40 | $24.76 | ASP | Q4 2023 – Q4 2026 | ListedAmpicillin Sodium |
| 72485-0423-10 | Ampicillin SodiumArmas Pharmaceuticals Inc. | 1 × 1 | 20 | 20 | $12.38 | ASP | Q4 2025 – Q4 2026 | ListedAmpicillin |
| 70860-0112-15 | Ampicillin SodiumAthenex Pharmaceutical Division, LLC | 1 × 10 | 0.5 | 5 | $3.09 | ASP | Q1 2021 – Q4 2026 | Excluded listingAmpicillin |
| 70860-0113-15 | Ampicillin SodiumAthenex Pharmaceutical Division, LLC | 1 × 10 | 1 | 10 | $6.19 | ASP | Q1 2021 – Q4 2026 | Excluded listingAmpicillin |
| 70860-0114-15 | Ampicillin SodiumAthenex Pharmaceutical Division, LLC | 1 × 10 | 2 | 20 | $12.38 | ASP | Q1 2021 – Q4 2026 | Excluded listingAmpicillin |
| 70860-0115-26 | Ampicillin SodiumAthenex Pharmaceutical Division, LLC | 1 × 10 | 4 | 40 | $24.76 | ASP | Q1 2021 – Q4 2026 | Excluded listingAmpicillin |
| 70860-0118-99 | Ampicillin SodiumAthenex Pharmaceutical Division, LLC | 1 × 1 | 20 | 20 | $12.38 | ASP | Q1 2021 – Q4 2026 | Excluded listingAmpicillin |
| 83634-0100-99 | Ampicillin SodiumAvenacy Inc. | 1 × 1 | 20 | 20 | $12.38 | ASP | Q4 2025 – Q4 2026 | ListedAmpicillin |
| 72572-0016-10 | Ampicillin SodiumCivica, Inc. | 1 × 10 | 2 | 20 | $12.38 | ASP | Q3 2021 – Q4 2026 | ListedAmpicillin |
| 72572-0017-10 | Ampicillin SodiumCivica, Inc. | 1 × 10 | 4 | 40 | $24.76 | ASP | Q3 2021 – Q4 2026 | ListedAmpicillin |
| 72572-0093-10 | Ampicillin SodiumCivica, Inc. | 1 × 10 | 2 | 20 | $12.38 | ASP | Q4 2026 | ListedAmpicillin sodium |
| 72572-0094-10 | Ampicillin SodiumCivica, Inc. | 1 × 10 | 4 | 40 | $24.76 | ASP | Q2 2026 – Q4 2026 | ListedAmpicillin Sodium |
| 55150-0113-10 | Ampicillin SodiumEugia US LLC | 1 × 10 | 2 | 20 | $12.38 | ASP | Q1 2021 – Q4 2026 | ListedAmpicillin |
| 55150-0114-20 | Ampicillin SodiumEugia US LLC | 1 × 10 | 4 | 40 | $24.76 | ASP | Q1 2021 – Q4 2026 | ListedAmpicillin |
| 55150-0115-99 | Ampicillin SodiumEugia US LLC | 1 × 10 | 20 | 200 | $123.80 | ASP | Q1 2021 – Q4 2026 | ListedAmpicillin |
| 65219-0014-10 | Ampicillin SodiumFreseniUS Kabi USA, LLC | 1 × 10 | 0.5 | 5 | $3.09 | ASP | Q1 2021 – Q4 2026 | ListedAmpicillin |
| 65219-0016-10 | Ampicillin SodiumFreseniUS Kabi USA, LLC | 1 × 10 | 1 | 10 | $6.19 | ASP | Q2 2021 – Q4 2026 | ListedAmpicillin |
| 65219-0018-10 | Ampicillin SodiumFreseniUS Kabi USA, LLC | 1 × 10 | 2 | 20 | $12.38 | ASP | Q1 2021 – Q4 2026 | ListedAmpicillin |
| 65219-0020-23 | Ampicillin SodiumFreseniUS Kabi USA, LLC | 1 × 10 | 4 | 40 | $24.76 | ASP | Q1 2021 – Q4 2026 | ListedAmpicillin |
| 00404-9803-99 | Ampicillin SodiumHenry Schein Inc. | 1 × 1 | 2 | 2 | $1.24 | ASP | Q1 2025 – Q4 2026 | Excluded listingAmpicillin |
| 00404-9816-99 | Ampicillin SodiumHenry Schein Inc. | 1 × 1 | 2 | 2 | $1.24 | ASP | Q3 2023 – Q4 2026 | Excluded listingAmpicillin |
| 00404-9818-99 | Ampicillin SodiumHenry Schein Inc. | 1 × 1 | 4 | 4 | $2.48 | ASP | Q3 2023 – Q4 2026 | ListedAmpicillin |
| 23155-0915-41 | Ampicillin SodiumHeritage Pharmaceuticals Inc. | 1 × 10 | 1 | 10 | $6.19 | ASP | Q4 2025 – Q4 2026 | ListedAmpicillin |
| 23155-0916-41 | Ampicillin SodiumHeritage Pharmaceuticals Inc. | 1 × 10 | 2 | 20 | $12.38 | ASP | Q4 2025 – Q4 2026 | ListedAmpicillin |
| 23155-0917-41 | Ampicillin SodiumHeritage Pharmaceuticals Inc. | 1 × 10 | 4 | 40 | $24.76 | ASP | Q4 2025 – Q4 2026 | ListedAmpicillin |
| 51662-1560-03 | Ampicillin SodiumHF Acquisition Co. LLC, DBA HealthFirst | 1 × 10 | 4 | 40 | $24.76 | ASP | Q4 2023 – Q4 2026 | ListedAmpicillin |
| 51662-1595-03 | Ampicillin SodiumHF Acquisition Co. LLC, DBA HealthFirst | 1 × 10 | 0.5 | 5 | $3.09 | ASP | Q1 2024 – Q4 2026 | ListedAmpicillin |
| 72603-0221-10 | Ampicillin SodiumNorthstar RxLLC | 1 × 10 | 1 | 10 | $6.19 | ASP | Q2 2025 – Q4 2026 | ListedAmpicillin |
| 72603-0363-10 | Ampicillin SodiumNorthstar RxLLC | 1 × 10 | 2 | 20 | $12.38 | ASP | Q1 2026 – Q4 2026 | ListedAmpicillin |
| 72603-0454-10 | Ampicillin SodiumNorthstar RxLLC | 1 × 10 | 4 | 40 | $24.76 | ASP | Q1 2026 – Q4 2026 | ListedAmpicillin |
| 72603-0578-01 | Ampicillin SodiumNorthstar RxLLC | 1 × 1 | 20 | 20 | $12.38 | ASP | Q1 2026 – Q4 2026 | ListedAmpicillin |
| 66794-0220-41 | Ampicillin SodiumPiramal Critical Care Inc | 1 × 10 | 0.5 | 5 | $3.09 | ASP | Q2 2022 – Q4 2026 | Excluded listingAmpicillin |
| 66794-0222-41 | Ampicillin SodiumPiramal Critical Care Inc | 1 × 10 | 2 | 20 | $12.38 | ASP | Q1 2021 – Q4 2026 | Excluded listingAmpicillin |
| 66794-0223-41 | Ampicillin SodiumPiramal Critical Care Inc | 1 × 10 | 4 | 40 | $24.76 | ASP | Q1 2021 – Q4 2026 | Excluded listingAmpicillin |
| 66794-0224-15 | Ampicillin SodiumPiramal Critical Care Inc | 1 × 1 | 20 | 20 | $12.38 | ASP | Q1 2022 – Q4 2026 | Excluded listingAmpicillin |
| 25021-0134-10 | Ampicillin SodiumSagent Pharmaceuticals | 1 × 10 | 0.5 | 5 | $3.09 | ASP | Q1 2021 – Q4 2026 | Excluded listingAmpicillin |
| 25021-0135-10 | Ampicillin SodiumSagent Pharmaceuticals | 1 × 10 | 1 | 10 | $6.19 | ASP | Q1 2021 – Q4 2026 | Excluded listingAmpicillin |
| 25021-0136-10 | Ampicillin SodiumSagent Pharmaceuticals | 1 × 10 | 2 | 20 | $12.38 | ASP | Q1 2021 – Q4 2026 | ListedAmpicillin |
| 25021-0137-20 | Ampicillin SodiumSagent Pharmaceuticals | 1 × 10 | 4 | 40 | $24.76 | ASP | Q1 2021 – Q4 2026 | ListedAmpicillin |
| 25021-0197-99 | Ampicillin SodiumSagent Pharmaceuticals | 1 × 1 | 20 | 20 | $12.38 | ASP | Q4 2025 – Q4 2026 | ListedAmpicillin Sodium |
| 00781-3402-95 | Ampicillin SodiumSandoz Inc. | 1 × 10 | 0.5 | 5 | $3.09 | ASP | Q1 2021 – Q4 2026 | ListedAmpicillin |
| 00781-3404-95 | Ampicillin SodiumSandoz Inc. | 1 × 10 | 2 | 20 | $12.38 | ASP | Q1 2021 – Q4 2026 | ListedAmpicillin |
| 00781-3407-95 | Ampicillin SodiumSandoz Inc. | 1 × 10 | 1 | 10 | $6.19 | ASP | Q1 2021 – Q4 2026 | ListedAmpicillin |
| 00781-3408-95 | Ampicillin SodiumSandoz Inc. | 1 × 10 | 4 | 40 | $24.76 | ASP | Q1 2021 – Q4 2026 | ListedAmpicillin |
| 00781-3409-95 | Ampicillin SodiumSandoz Inc. | 1 × 10 | 20 | 200 | $123.80 | ASP | Q1 2021 – Q4 2026 | ListedAmpicillin |
| 00781-3412-92 | Ampicillin SodiumSandoz Inc. | 1 × 10 | 2 | 20 | $12.38 | ASP | Q1 2021 – Q4 2026 | ListedAmpicillin |
| 00781-3413-92 | Ampicillin SodiumSandoz Inc. | 1 × 10 | 4 | 40 | $24.76 | ASP | Q1 2021 – Q4 2026 | ListedAmpicillin |
| 00781-9242-95 | Ampicillin SodiumSandoz Inc. | 1 × 10 | 0.5 | 5 | $3.09 | ASP | Q1 2021 – Q4 2026 | Excluded listingAmpicillin |
| 00781-9261-95 | Ampicillin SodiumSandoz Inc. | 1 × 10 | 2 | 20 | $12.38 | ASP | Q1 2021 – Q4 2026 | ListedAmpicillin |
| 00781-9273-95 | Ampicillin SodiumSandoz Inc. | 1 × 10 | 4 | 40 | $24.76 | ASP | Q1 2021 – Q4 2026 | ListedAmpicillin |
| 00781-9402-95 | Ampicillin SodiumSandoz Inc. | 1 × 10 | 0.5 | 5 | $3.09 | ASP | Q1 2021 – Q4 2026 | Excluded listingAmpicillin |
| 00781-9404-95 | Ampicillin SodiumSandoz Inc. | 1 × 10 | 2 | 20 | $12.38 | ASP | Q1 2021 – Q4 2026 | ListedAmpicillin |
| 00781-9407-95 | Ampicillin SodiumSandoz Inc. | 1 × 10 | 1 | 10 | $6.19 | ASP | Q1 2021 – Q4 2026 | Excluded listingAmpicillin |
| 00781-9408-95 | Ampicillin SodiumSandoz Inc. | 1 × 10 | 4 | 40 | $24.76 | ASP | Q1 2021 – Q4 2026 | ListedAmpicillin |
| 00781-9409-95 | Ampicillin SodiumSandoz Inc. | 1 × 10 | 20 | 200 | $123.80 | ASP | Q1 2021 – Q4 2026 | ListedAmpicillin |
| 00781-9412-92 | Ampicillin SodiumSandoz Inc. | 1 × 10 | 2 | 20 | $12.38 | ASP | Q1 2021 – Q4 2026 | ListedAmpicillin |
| 00781-9413-92 | Ampicillin SodiumSandoz Inc. | 1 × 10 | 4 | 40 | $24.76 | ASP | Q1 2021 – Q4 2026 | ListedAmpicillin |
| 44567-0100-10 | Ampicillin SodiumWG Critical Care, LLC | 1 × 10 | 0.5 | 5 | $3.09 | ASP | Q3 2025 – Q4 2026 | ListedAmpicillin |
| 44567-0101-10 | Ampicillin SodiumWG Critical Care, LLC | 1 × 10 | 1 | 10 | $6.19 | ASP | Q1 2021 – Q4 2026 | ListedAmpicillin |
| 44567-0102-10 | Ampicillin SodiumWG Critical Care, LLC | 1 × 10 | 2 | 20 | $12.38 | ASP | Q1 2021 – Q4 2026 | ListedAmpicillin |
| 44567-0103-10 | Ampicillin SodiumWG Critical Care, LLC | 1 × 10 | 4 | 40 | $24.76 | ASP | Q1 2021 – Q4 2026 | ListedAmpicillin |
| 44567-0104-01 | Ampicillin SodiumWG Critical Care, LLC | 1 × 1 | 20 | 20 | $12.38 | ASP | Q1 2021 – Q4 2026 | ListedAmpicillin |
Derived calculation “Derived $ / NDC” = billable units per NDC × the current payment limit. It is arithmetic for orientation, not a payment amount.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|
| 55150-0111-10 | Ampicillin SodiumAUROMEDICS PHARMA LLC | 1 × 10 | 0.5 | 5 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file |
Medicare coverage is set nationally (NCDs) and by each Medicare Administrative Contractor (LCDs and Billing & Coding articles). These links open the official documents.
Verification neededCodeRx links to coverage documents instead of copying them: CMS distributes their code lists under AMA, ADA, and AHA license terms that limit reuse. Medicare Advantage, Medicaid, and commercial plans set their own coverage and prior-authorization rules.
Changes detected between the CMS quarterly HCPCS files CodeRx has imported.
| Quarterly file | Change | CMS action code | Details |
|---|---|---|---|
| Q1 2023 | In earliest ingested file | N — No maintenance | Added date Jan 1, 1984 |
All imported releases, checksums, and import reports are listed on the data sources page.
Disclaimer. This application provides informational coding and reimbursement reference data. It does not constitute legal, clinical, coding, or billing advice. Codes, payment amounts, payer rules, and coverage policies can change. Verify all information with current CMS publications, the applicable payer, and your organization’s compliance policies before submitting a claim. CodeRx is not affiliated with or endorsed by CMS, FDA, Medicare, or any payer.
| CMS Policy |
An MUE is the most units CMS expects for this code for one patient on one date of service by the same provider in most correctly reported claims. CMS MUE program
| — |
| Q2 2026 | Apr 1, 2026 – Jun 30, 2026 | $0.642 | 500 MG | 20% | +8.6% | — |
|---|
| Q1 2026 | Jan 1, 2026 – Mar 31, 2026 | $0.591 | 500 MG | 20% | +8.2% | — |
|---|
| Q4 2025 | Oct 1, 2025 – Dec 31, 2025 | $0.546 | 500 MG | 20% | +11.7% | — |
|---|
| Q3 2025 | Jul 1, 2025 – Sep 30, 2025 | $0.489 | 500 MG | 20% | −18.1% | — |
|---|
| Q2 2025 | Apr 1, 2025 – Jun 30, 2025 | $0.597 | 500 MG | 20% | −16.4% | — |
|---|
| Q1 2025 | Jan 1, 2025 – Mar 31, 2025 | $0.714 | 500 MG | 20% | −8.9% | — |
|---|
| Q4 2024 | Oct 1, 2024 – Dec 31, 2024 | $0.784 | 500 MG | 20% | −10.9% | — |
|---|
| Q3 2024 | Jul 1, 2024 – Sep 30, 2024 | $0.880 | 500 MG | 20% | −11.7% | — |
|---|
| Q2 2024 | Apr 1, 2024 – Jun 30, 2024 | $0.997 | 500 MG | 20% | −1.4% | — |
|---|
| Q1 2024 | Jan 1, 2024 – Mar 31, 2024 | $1.011 | 500 MG | 20% | +7.0% | — |
|---|
| Q4 2023 | Oct 1, 2023 – Dec 31, 2023 | $0.945 | 500 MG | 20% | +20.8% | — |
|---|
| Q3 2023 | Jul 1, 2023 – Sep 30, 2023 | $0.782 | 500 MG | 20% | −15.0% | — |
|---|
| Q2 2023 | Apr 1, 2023 – Jun 30, 2023 | $0.920 | 500 MG | 20% | +26.4% | — |
|---|
| Q1 2023 | Jan 1, 2023 – Mar 31, 2023 | $0.728 | 500 MG | — | −4.5% | — |
|---|
| Q4 2022 | Oct 1, 2022 – Dec 31, 2022 | $0.762 | 500 MG | — | +2.1% | — |
|---|
| Q3 2022 | Jul 1, 2022 – Sep 30, 2022 | $0.746 | 500 MG | — | +15.5% | — |
|---|
| Q2 2022 | Apr 1, 2022 – Jun 30, 2022 | $0.646 | 500 MG | — | −9.1% | — |
|---|
| Q1 2022 | Jan 1, 2022 – Mar 31, 2022 | $0.711 | 500 MG | — | −11.9% | — |
|---|
| Q4 2021 | Oct 1, 2021 – Dec 31, 2021 | $0.807 | 500 MG | — | −4.3% | — |
|---|
| Q3 2021 | Jul 1, 2021 – Sep 30, 2021 | $0.843 | 500 MG | — | −5.9% | — |
|---|
| Q2 2021 | Apr 1, 2021 – Jun 30, 2021 | $0.896 | 500 MG | — | +1.1% | — |
|---|
| Q1 2021 | Jan 1, 2021 – Mar 31, 2021 | $0.886 | 500 MG | — | — | — |
|---|
| 55150-0112-10 | Ampicillin SodiumAUROMEDICS PHARMA LLC | 1 × 10 | 1 | 10 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | ListedAmpicillin |
|---|
| 63323-0704-08 | Ampicillin SodiumFRESENIUS KABI | 1 × 10 | 2 | 20 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | Excluded listingAmpicillin |
|---|
| 63323-0705-08 | AMPICILLIN SODIUMFRESENIUS KABI | 1 × 10 | 4 | 40 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | Excluded listingAmpicillin |
|---|
| 63323-0707-20 | AMPICILLIN SODIUMFRESENIUS KABI | 1 × 10 | 0.5 | 5 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | Excluded listingAmpicillin |
|---|
| 63323-0708-00 | Ampicillin SodiumFRESENIUS KABI | 1 × 10 | 1 | 10 | ASP | Q1 2021 – Q4 2022Not in Q4 2026 file | Excluded listingAmpicillin |
|---|
| 67457-0350-10 | Ampicillin SodiumMYLAN INSTITUTIONAL LLC | 1 × 10 | 1 | 10 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | Excluded listingAmpicillin |
|---|
| 67457-0353-10 | Ampicillin SodiumMYLAN INSTITUTIONAL LLC | 1 × 10 | 0.5 | 5 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | Excluded listingAmpicillin |
|---|
| 67457-0351-10 | Ampicillin SodiumMylan Pharmaceuticals Inc. | 1 × 10 | 2 | 20 | ASP | Q1 2021 – Q4 2025Not in Q4 2026 file | Excluded listingAmpicillin |
|---|
| 67457-0352-10 | Ampicillin SodiumMylan Pharmaceuticals Inc. | 1 × 10 | 4 | 40 | ASP | Q1 2021 – Q4 2025Not in Q4 2026 file | Excluded listingAmpicillin |
|---|
| 67457-0404-10 | Ampicillin SodiumMylan Pharmaceuticals Inc. | 1 × 1 | 20 | 20 | ASP | Q1 2021 – Q4 2025Not in Q4 2026 file | Excluded listingAmpicillin Sodium |
|---|
| 00409-3718-01 | Ampicillin SodiumPfizer Inc | 1 × 10 | 1 | 10 | ASP | Q1 2021 – Q4 2025Not in Q4 2026 file | Excluded listingAmpicillin |
|---|
| 00409-3720-01 | Ampicillin SodiumPfizer Inc | 1 × 10 | 4 | 40 | ASP | Q1 2021 – Q1 2025Not in Q4 2026 file | Excluded listingAmpicillin |
|---|
| 00409-3725-01 | Ampicillin SodiumPfizer Inc | 1 × 10 | 20 | 200 | ASP | Q1 2021 – Q1 2025Not in Q4 2026 file | Excluded listingAmpicillin |
|---|
| 00409-3719-01 | Ampicillin SodiumPFIZER INC. | 1 × 10 | 0.5 | 5 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | Excluded listingAmpicillin |
|---|
| 00409-3726-01 | Ampicillin SodiumPFIZER INC. | 1 × 10 | 2 | 20 | ASP | Q1 2021 – Q4 2024Not in Q4 2026 file | Excluded listingAmpicillin |
|---|
| 66794-0221-41 | Ampicillin SodiumPiramal Critical Care Inc | 1 × 10 | 1 | 10 | ASP | Q1 2022 – Q4 2024Not in Q4 2026 file | Excluded listingAmpicillin |
|---|
| 00781-3400-95 | Ampicillin SodiumSandoz Inc. | 1 × 10 | 0.25 | 3 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file | Excluded listingAmpicillin |
|---|
| 00781-9250-95 | Ampicillin SodiumSandoz Inc. | 1 × 10 | 1 | 10 | ASP | Q1 2021 – Q4 2025Not in Q4 2026 file | Excluded listingAmpicillin |
|---|
| 00781-9401-95 | Ampicillin SodiumSandoz Inc. | 1 × 10 | 0.25 | 3 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file | Excluded listingAmpicillin |
|---|
| 44567-0104-10 | Ampicillin for InjectionWG CRITICAL CARE | 1 × 10 | 20 | 200 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | Not found |
|---|
| 70594-0084-02 | Ampicillin SodiumXellia Pharmaceuticals USA, LLC. | 1 × 10 | 0.5 | 5 | ASP | Q3 2022 – Q2 2026Not in Q4 2026 file | Excluded listingAmpicillin |
|---|
| 70594-0085-02 | Ampicillin SodiumXellia Pharmaceuticals USA, LLC. | 1 × 10 | 1 | 10 | ASP | Q3 2022 – Q2 2026Not in Q4 2026 file | Excluded listingAmpicillin |
|---|
| 70594-0086-02 | Ampicillin SodiumXellia Pharmaceuticals USA, LLC. | 1 × 10 | 2 | 20 | ASP | Q3 2022 – Q1 2025Not in Q4 2026 file | Excluded listingAmpicillin |
|---|
| 70594-0087-02 | Ampicillin SodiumXellia Pharmaceuticals USA, LLC. | 1 × 10 | 4 | 40 | ASP | Q3 2022 – Q2 2026Not in Q4 2026 file | Excluded listingAmpicillin |
|---|
| 70594-0088-01 | Ampicillin SodiumXellia Pharmaceuticals USA, LLC. | 1 × 1 | 20 | 20 | ASP | Q3 2022 – Q2 2026Not in Q4 2026 file | Excluded listingAmpicillin |
|---|